Pharmacoepidemiology of statins in Еast region of Kazakhstan

Фармакоэпидемиология статинов в Восточном регионе Казахстана
Assem Makhatova 1, Raikhan Tuleutayeva 1, Aigerim Mussina 1, Andrey Gorbatenko 1
More Detail
1 Department of Pharmacology and Evidence-Based Medicine, Semey State Medical University, Semey, Republic of Kazakhstan
J CLIN MED KAZ, Volume 1, Issue 47, pp. 36-40. https://doi.org/10.23950/1812-2892-JCMK-00540
OPEN ACCESS 4215 Views 3332 Downloads
Download Full Text (PDF)

ABSTRACT

Objective: To determine frequency, structure of antihyperholesterinemic therapy in the east region of Kazakhstan and compliance of the patients.
Material and Methods: The pharmacoepidemiological analysis was carried out on the basis of archival documents (medical history, outpatient cards) of 14 treatment and prevention institutions in Semey city of the East Kazakhstan region. A total of 3458 units of primary material were analyzed. The study included medical documentation of people with the diagnosis of ischemic heart disease, arterial hypertension, arterial atherosclerosis of lower limbs and other chronic diseases, as well as clinically healthy individuals with a study of the content of cholesterol in the blood. To determine adherence, the Moriski-Green test is used.
Results: It was revealed that the frequency of prescribing antihypercholesterolemic drugs (statins) in the conditions of Semey city is 80.7% of cases from the number of persons with clinical indications for their use. Atorvastatin (89.7%) prevailed in the structure of antihypercholesterolemic therapy in patients with hypercholesterolemia and clinically manifested atherosclerosis. A low adherence to statin therapy has been revealed, reaching only 46.6% of the number of appointments and decreasing to 39.9% in individuals without clinical manifestations of atherosclerosis. The overall frequency of regular statin use in the group average, taking into account prescriptions and adherence, is 37.6% of the number of people with clinical indications and depends on the clinical diagnosis.
Conclusion: It is necessary to implement measures to correct the approaches of doctors to the appointment of antihypercholesterolemic therapy and work with patients aimed at increasing adherence to treatment.
Keywords: pharmacoepidemiology, statins, adherence

CITATION

Makhatova A, Tuleutayeva R, Mussina A, Gorbatenko A. Pharmacoepidemiology of statins in Еast region of Kazakhstan. Journal of Clinical Medicine of Kazakhstan. 2018;1(47):36-40. https://doi.org/10.23950/1812-2892-JCMK-00540

REFERENCES

  • Ponomaryova A.I., Kompaniets O.G., Linchak R.M., Agafonova G.A. Farmakojepidemiologija statinov u pacientov s gipertonicheskoj bolezn’ju i dislipidemiej (Statins pharmacoepidemiology in patients with hypertonic disease an dyslipidemia). Kardiologija. 2015. 10:25-31.
  • Chou R, Dana T, Blazina I. et al. Statins for Prevention of Cardiovascular Disease in Adults: Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2016. 15;316(19):2008-2024.
  • Doyle MN, Bhimji SS. Statin Medications. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. 2017.
  • Miller PE, Martin SS. Approach to Statin Use in 2016: an Update. Curr Atheroscler Rep. 2016; 18(5):20.
  • Kazi DS, Penko JM, Bibbins-Domingo K. Statins for Primary Prevention of Cardiovascular Disease: Review of Evidence and Recommendations for Clinical Practice. Med Clin North Am. 2017; 101(4):689-699.
  • Davies JT, Delfino SF, Feinberg CE. et al. Current and Emerging Uses of Statins in Clinical Therapeutics: A Review. Lipid Insights. 2016; 9: 13-29.
  • Simoens S, Sinnaeve PR. Generic atorvastatin, the Belgian statin market and the cost-effectiveness of statin therapy. Cardiovasc Drugs Ther. 2013; 27(1):49-60.
  • Lin I, Sung J, Sanchez RJ. et al. Patterns of Statin Use in a Real-World Population of Patients at High Cardiovascular Risk. J Manag Care Spec Pharm; 22(6):685-698.
  • Anderson TJ, Grégoire J, Pearson GJ. et al. 2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult. Can J Cardiol. 2016; 32(11):1263-1282.
  • Wadhera RK, Steen DL, Khan I. et al. A review of low-density lipoprotein cholesterol, treatment strategies, and its impact on cardiovascular disease morbidity and mortality. J Clin Lipidol. 2016; 10(3):472-89.
  • Bitto A, Pallio G, Messina S. et al. Genomic Variations Affecting Biological Effects of Statins. Curr Drug Metab. 2016; 17(6):566-72.
  • Swerdlow DI, Preiss D. Genetic insights into statin-associated diabetes risk. Curr Opin Lipidol. 2016; 27(2):125-30.
  • EAS/ESC Guidelines for the Management of Dyslipidaemias. Eur. Heart J. 2016; 37:2999-3058.
  • Nayor M, Vasan RS. Recent Update to the US Cholesterol Treatment Guidelines: A Comparison With International Guidelines. Circulation. 2016; 133(18):1795-806.
  • Toth PP. Novel Therapies for Low-Density Lipoprotein Cholesterol Reduction. Am J Cardiol. 2016; 118(6):19A-32A.
  • Retornaz F, Beliard S, Gremeaux E. et al. Statin and cardiovascular diseases after 75 years. Rev Med Interne. 2016; 37(9):625-31.
  • Li X, Stürmer T, Brookhart MA. Evidence of sample use among new users of statins: implications for pharmacoepidemiology. Med Care. 2014; 52(9):773-80.
  • Graham IM, Catapano AL, Wong ND. Current guidelines on prevention with a focus on dyslipidemias. Cardiovasc Diagn Ther. 2017; 7(1):4-10.
  • Sehra D, Sehra S, Sehra ST. Cardiovascular pleiotropic effects of statins and new onset diabetes: is there a common link: do we need to evaluate the role of KATP channels? Expert Opin Drug Saf. 2017; 16(7):823-831.
  • Bedi O, Dhawan V, Sharma PL, Kumar P. Pleiotropic effects of statins: new therapeutic targets in drug design. Naunyn Schmiedebergs Arch Pharmacol. 2016; 389(7):695-712.
  • Babcook MA, Joshi A, Montellano JA, Shankar E, Gupta S. Statin Use in Prostate Cancer: An Update. Nutr Metab Insights. 2016; 9:43-50.
  • Oscanoa Espinoza TJ, Paredes-Pérez N, Lizaraso-Soto F. Safety of statins. Rev Fac Cien Med Univ Nac Cordoba. 2016; 73(4):263-278.
  • Laakso M, Kuusisto J. Diabetes Secondary to Treatment with Statins. Curr Diab Rep. 2017; 17(2):10.
  • Bosworth HB, Brown JN, Danus S. et al. Evaluation of a packaging approach to improve cholesterol medication adherence. Am J Manag Care. 2017; 23(9):280-286.
  • Ofori-Asenso R, Jakhu A, Zomer E. et al. Adherence and Persistence among Statin Users aged 65 years and over: A Systematic Review and Meta-analysis. J Gerontol A Biol Sci Med Sci. 2017.
  • Colantonio LD, Huang L, Monda KL, et al. Adherence to High-Intensity Statins Following a Myocardial Infarction Hospitalization Among Medicare Beneficiaries. JAMA Cardiol. 2017; 2(8):890-895.
  • Tran YB, Frial T, Miller PS. Statin’s cost-effectiveness: a Canadian analysis of commonly prescribed generic and brand name statins. Can J Clin Pharmacol. 2007; 14(2):205-14.